{"brief_title": "A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)", "brief_summary": "To assess the tolerance and toxicity profile of deoxy-3'-fluorothymidine (FLT) after multiple oral dosing for 16 weeks. To characterize the steady-state pharmacokinetics of FLT after multiple oral doses. To assess the effect of FLT on immunologic and virologic markers of HIV infection (CD4+ lymphocyte count, p24 antigen, viremia) in patients with AIDS or AIDS related complex (ARC) after multiple oral dosing for 16 weeks.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Alovudine"], "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis. - Up to 14 days of systemic therapy for minor opportunistic infections such as candidiasis, mucocutaneous Herpes simplex or cutaneous Herpes zoster infections. Patients must have the following: - AIDS or AIDS related complex (ARC) as defined by the CDC. - Positive antibody to HIV as determined by a commercially licensed ELISA test kit, confirmed by Western blot analysis. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Symptomatic visceral Kaposi's sarcoma or progression of Kaposi's sarcoma within the month prior to study entry (progression is defined as more than a 25 percent increase in the product of bidirectional measurement of indicator lesions and/or more than a 25 percent increase in the number of new lesions). - Concurrent neoplasms other than Kaposi's sarcoma or basal cell carcinoma of the skin. Patients who have had a malignancy in the past that has been in complete remission for 1 year without therapy may be enrolled. - Signs or symptoms of neuropathy and a Vibratron 2 score = or > 4 for either great toe. Concurrent Medication: Excluded: - Acute therapy for AIDS-related infection. - Systemic maintenance therapy for AIDS-defining opportunistic infection. - Recombinant erythropoietin. - Long term therapy with either aspirin or probenecid. Concurrent Treatment: Excluded: - Blood transfusion more than once per month. Patients with the following are excluded: - Symptomatic visceral Kaposi's sarcoma or progression of Kaposi's sarcoma within the month prior to study entry. - Unwilling to sign an informed consent or patients unwilling to be followed at the medical center where they were enrolled for the duration of the study and follow-up as required. - History of intolerance to zidovudine (AZT) at any dose as demonstrated by an AZT related decrease in hemoglobin levels of at least 2 g/dl or AZT related depression of neutrophils of at least 200 cells/mm3 to < 750 cells/mm3 which required discontinuation of AZT therapy. - Diseases or conditions listed in Exclusion Co-Existing Conditions. Prior Medication: Excluded: - Antiretroviral agents within 14 days of study entry. - Immunomodulating agents or corticosteroids within 30 days prior to study entry. - Treatment for acute Pneumocystis carinii pneumonia within 2 weeks prior to study entry. Prior Treatment: Excluded: - Blood transfusions within 7 days prior to study entry. - Radiation therapy for Kaposi's sarcoma within 30 days prior to study entry. Active substance abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Acquired Immunodeficiency Syndrome", "mesh_term": ["HIV Infections", "Immunologic Deficiency Syndromes", "AIDS-Related Complex", "Acquired Immunodeficiency Syndrome", "Alovudine", "Dideoxynucleosides"], "id": "NCT00002254"}